CMND

Clearmind Medicine Welcomes  President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Clearmind Gains Regulatory Momentum with Trump's Executive Order on Psychedelics

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Clearmind Medicine&#039;s recognition in recent legislation and Trump&#039;s Executive Order signifies a critical regulatory shift favoring psychedelic therapies. This momentum could lead to enhanced market opportunities and expedited development timelines for their CMND-100 treatment, impacting both access and investor sentiment significantly.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Clearmind applauds Trump&#039;s order to streamline FDA processes for psychedelic therapies.</li><li>The order aims to enhance access to breakthrough treatments for mental health.</li><li>Clearmind&#039;s MEAI recognized in congressional legislation for expanding treatment avenues.</li><li>CMND-100 is in clinical trials for alcohol use disorder at top institutions.</li><li>Clearmind emphasizes its commitment to developing non-hallucinogenic neuroplastogens.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Yale School of Medicine (N/A)</strong>: Collaborating with Clearmind on CMND-100 clinical trials.</li><li><strong>Johns Hopkins University (N/A)</strong>: Key institution involved in CMND-100&#039;s trial implementation.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This article falls under &#039;Corporate Developments&#039; as it discusses significant regulatory advances impacting Clearmind&#039;s operations. The evolving regulatory landscape is critical for biotech firms in mental health therapeutics, especially those pursuing innovative solutions like psychedelic treatments.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Trump&#039;s Executive Order could significantly expedite CMND-100&#039;s FDA approval pathway.</li><li>Legislative support for MEAI may bolster Clearmind&#039;s credibility and investor confidence.</li><li>Positive trial results from CMND-100 could lead to rapid stock appreciation.</li><li>Increased focus on mental health solutions may elevate demand for CMND&#039;s therapies.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Executive Order signed on April 18, 2026, by President Trump.</li><li>MEAI mentioned in bipartisan Congressional legislation, H.R. 7091.</li><li>Clearmind&#039;s CMND-100 currently in FDA-approved Phase I/IIa trials.</li><li>Clinical trials being conducted at Yale and Johns Hopkins Universities.</li><li>Company holds 31 granted patents across 19 patent families.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy CMND ahead of potential breakthroughs and increased FDA engagement over the next year.</p>
  </section>
</section>


<article>
    <h2>Clearmind Medicine Applauds Major Executive Order Supporting Psychedelic Innovation</h2>
    <p>Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/CMND">CMND</a>), a leading clinical-stage psychedelic biotech firm, has expressed its strong approval of President Donald J. Trump's recent Executive Order. Signed on April 18, 2026, this order, titled <em>Accelerating Medical Treatments for Serious Mental Illness</em>, orders the U.S. Food and Drug Administration (FDA) to fast-track the review processes for psychedelic drugs classified as breakthrough therapies, thus enhancing patient access pathways.</p>

    <h3>Significance of the Executive Order</h3>
    <p>Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated, “We are pleased to see psychedelic medicines, including non-hallucinogenic neuroplastogens, gaining increasing mainstream recognition and regulatory momentum. This Executive Order underscores the growing acknowledgment of the urgent need to remove barriers and deliver innovative treatments to millions of Americans, particularly veterans suffering from treatment-resistant PTSD, depression, and alcohol use disorder.”</p>
    
    <h3>Advancements in Legislative Support</h3>
    <p>The Executive Order aligns with Clearmind Medicine’s recent accomplishments, particularly in February 2026 when the Company’s proprietary compound MEAI (5-methoxy-2-aminoindane or 5-MeO-AI) was cited in bipartisan U.S. Congressional legislation (H.R. 7091 – Expanding Veterans' Access to Emerging Treatments Act). This crucial legislation aims to facilitate VA-supported clinical trials and broaden access for innovative therapies targeting alcohol use disorder.</p>

    <h3>Commitment to Development</h3>
    <p>Dr. Zuloff-Shani added, "At Clearmind, we remain deeply committed to rigorous, science-driven development of our lead candidate CMND-100 (MEAI) and our broader pipeline of psychedelic non-hallucinogenic neuroplastogens." The company aims for continued collaboration with regulators and policymakers to ensure that breakthrough therapies reach the patients who need them most.</p>

    <h3>Ongoing Clinical Trials</h3>
    <p>Currently, Clearmind Medicine is progressing with FDA-approved Phase I/IIa clinical trials for CMND-100 focused on alcohol use disorder. These trials are taking place at prestigious institutions such as Yale School of Medicine and Johns Hopkins University.</p>

    <h3>About Clearmind Medicine Inc.</h3>
    <p>Clearmind Medicine is dedicated to uncovering non-hallucinogenic, neuroplastogen-derived therapeutics aimed at addressing pressing health issues, including alcohol use disorder. The company strives to research and develop these compounds to potentially commercialize them as FDA-regulated medicines, foods, or supplements.</p>
    
    <ul>
        <li>Current intellectual property portfolio includes nineteen patent families and 31 granted patents.</li>
        <li>The company will pursue additional patents as necessary and remains open to acquiring more intellectual property.</li>
        <li>Shares of Clearmind are publicly traded on Nasdaq under the symbol <strong>CMND</strong>.</li>
    </ul>

    <h3>Contact Information</h3>
    <p>For further inquiries, visit: <a href="https://www.clearmindmedicine.com" rel="nofollow" target="_blank"><u>Clearmind Medicine</u></a> or reach out to:</p>
    <p>Investor Relations<br>
    <a href="mailto:invest@clearmindmedicine.com" rel="nofollow"><u>invest@clearmindmedicine.com</u></a><br>
    <a href="https://www.clearmindmedicine.com" rel="nofollow" target="_blank"><u>www.clearmindmedicine.com</u></a>
    </p>

    <h3>Forward-Looking Statements</h3>
    <p>This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act. Such statements include expected development timelines, potential collaboration outcomes, and the future success of clinical trials. Actual results may differ significantly due to various risks and uncertainties.</p>
</article>

Clearmind Medicine's recognition in recent legislation and Trump's Executive Order signifies a critical regulatory shift favoring psychedelic therapies. This momentum could lead to enhanced market opportunities and expedited development timelines for their CMND-100 treatment, impacting both access and investor sentiment significantly.

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News